Literature DB >> 1376911

Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue.

J Brolin1, L Skoog, P Ekman.   

Abstract

The relative distribution of androgen (AR), progesterone (PR), and estrogen receptors (ER) was localized and estimated in human prostate tissue by immunohistochemistry in five normal tissue samples, in eight benign hyperplastic (BPH) samples, in nine primary cancers, and in seven prostate cancer metastases. Moreover, three prostatic cancer cell lines (LNCaP, DU 145, and PC 3) were analyzed. A comparison between the results obtained by radioligand binding assays and immunohistochemistry was performed for the AR and PR. Using immunohistochemistry, the AR was exclusively detected in the nuclei of both benign and malignant prostatic epithelial cells. The highest proportion of AR-positive cells was found in BPH and in prostate cancer metastases as compared with normal prostatic tissue. In a majority of the cases, the PR was only present in the nuclei of stromal cells. Benign hyperplastic prostates contained higher proportions of PR-positive cells as compared with primary carcinoma. PR was sparse in epithelial cells. ER-positive stromal cell nuclei were only detected in carcinomatous prostates. A few ER-positive epithelial cell nuclei were found in one sample each of a BPH and normal prostate. All cells from the androgen-dependent, LNCaP, cell line and a majority of the cells from the androgen-independent, DU 145, cell line were AR-positive. In contrast, the cells from the androgen-independent, PC 3, cell line were all AR-negative. All three cell lines were PR- and ER-negative. The radioligand binding technique detected the AR in extracts from both the cytosol and the nucleus. Again BPH contained higher amounts of AR as compared with normal prostatic tissue. The LNCaP cells contained high amounts of cytosolic AR while cells from the DU 145 and PC 3 cell lines lacked detectable AR as estimated by biochemical techniques. There seemed to be a discrepancy between biochemically measured and immunohistochemically estimated receptor content.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376911     DOI: 10.1002/pros.2990200404

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  23 in total

1.  Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.

Authors:  Rajeev Kumar; Vikas Verma; Amit Sarswat; J P Maikhuri; Ashish Jain; Rajeev K Jain; V L Sharma; Diwakar Dalela; Gopal Gupta
Journal:  Invest New Drugs       Date:  2010-12-23       Impact factor: 3.850

Review 2.  Precursor lesions for prostate cancer.

Authors:  M R Feneley; C Busch
Journal:  J R Soc Med       Date:  1997-10       Impact factor: 5.344

3.  Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.

Authors:  H Bonkhoff; T Fixemer; I Hunsicker; K Remberger
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

Review 4.  Estrogen and androgen signaling in the pathogenesis of BPH.

Authors:  Clement K M Ho; Fouad K Habib
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

5.  Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.

Authors:  Tristan M Nicholson; Priyanka D Sehgal; Sally A Drew; Wei Huang; William A Ricke
Journal:  Differentiation       Date:  2013-06-20       Impact factor: 3.880

6.  Expression of estrogen receptor β and Ki 67 in benign & malignant human prostate lesions by immunohistochemistry.

Authors:  Shrruti K Grover; Sarla Agarwal; Sanjay Gupta; Neelam Wadhwa; Nivedita Sharma
Journal:  Pathol Oncol Res       Date:  2014-12-20       Impact factor: 3.201

7.  Tissue-specific quantification and localization of androgen and estrogen receptors in prostate cancer.

Authors:  Priyanka D Sehgal; Tyler M Bauman; Tristan M Nicholson; Jordan E Vellky; Emily A Ricke; Weiping Tang; Wei Xu; Wei Huang; William A Ricke
Journal:  Hum Pathol       Date:  2019-05-03       Impact factor: 3.466

8.  Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell.

Authors:  Alejandro Godoy; Anica Watts; Paula Sotomayor; Viviana P Montecinos; Wendy J Huss; Sergio A Onate; Gary J Smith
Journal:  Endocrinology       Date:  2008-02-21       Impact factor: 4.736

Review 9.  Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk.

Authors:  Mitchell S Steiner; Sharan Raghow
Journal:  World J Urol       Date:  2003-02-14       Impact factor: 4.226

10.  Computer based receptogram approach: an objective way of assessing immunohistochemistry of androgen receptor staining and its correlation with hormonal response in metastatic carcinoma of prostate.

Authors:  G Nabi; A Seth; A K Dinda; N P Gupta
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.